Your browser is no longer supported. Please, upgrade your browser.
PDLI PDL BioPharma, Inc. daily Stock Chart
PDL BioPharma, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own0.90% Shs Outstand115.91M Perf Week1.58%
Market Cap355.78M Forward P/E- EPS next Y-0.09 Insider Trans0.00% Shs Float110.01M Perf Month-3.30%
Income-85.60M PEG- EPS next Q0.06 Inst Own86.00% Short Float11.91% Perf Quarter10.65%
Sales51.80M P/S6.87 EPS this Y-25.60% Inst Trans5.03% Short Ratio12.13 Perf Half Y42.08%
Book/sh3.63 P/B0.89 EPS next Y83.30% ROA- Target Price- Perf Year82.53%
Cash/sh0.95 P/C3.38 EPS next 5Y14.00% ROE- 52W Range1.71 - 3.78 Perf YTD19.53%
Dividend- P/FCF- EPS past 5Y-18.30% ROI-17.00% 52W High-14.81% Beta0.93
Dividend %- Quick Ratio13.30 Sales past 5Y-37.70% Gross Margin2.70% 52W Low88.29% ATR0.14
Employees75 Current Ratio13.70 Sales Q/Q-30.70% Oper. Margin- RSI (14)47.58 Volatility4.57% 4.16%
OptionableYes Debt/Eq0.03 EPS Q/Q-62.00% Profit Margin- Rel Volume0.80 Prev Close3.15
ShortableYes LT Debt/Eq0.03 EarningsAug 06 AMC Payout- Avg Volume1.08M Price3.22
Recom- SMA20-1.23% SMA50-1.72% SMA20010.28% Volume866,527 Change2.22%
Dec-22-16Resumed Piper Jaffray Overweight
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $5 → $4
Feb-02-16Reiterated RBC Capital Mkts Sector Perform $6 → $5
Nov-05-15Reiterated RBC Capital Mkts Sector Perform $7 → $6
Oct-16-15Reiterated RBC Capital Mkts Sector Perform $8 → $7
Jan-20-11Upgrade RBC Capital Mkts Sector Perform → Outperform $6 → $6
Sep-10-10Initiated RBC Capital Mkts Sector Perform $6
Mar-27-09Upgrade Lazard Capital Mkts Hold → Buy $8
Mar-03-09Reiterated Wedbush Morgan Buy $15 → $9
Mar-03-09Reiterated JMP Securities Mkt Outperform $16 → $9
Jan-05-09Upgrade JP Morgan Underweight → Neutral
Dec-10-08Reiterated Credit Suisse Neutral $11 → $12
Sep-11-08Downgrade JP Morgan Neutral → Underweight
Jun-13-08Downgrade Credit Suisse Outperform → Neutral
May-12-08Reiterated Lehman Brothers Equal-Weight $16 → $12
Apr-22-08Downgrade Wachovia Outperform → Mkt Perform
Apr-11-08Reiterated Credit Suisse Outperform $19 → $16
Mar-10-08Downgrade Susquehanna Financial Positive → Neutral
Mar-06-08Reiterated BMO Capital Markets Market Perform $18 → $14
Mar-05-08Downgrade Lehman Brothers Overweight → Equal-weight $21 → $13
Sep-10-20 08:30AM  
Sep-09-20 08:30AM  
Aug-31-20 09:00AM  
Aug-28-20 08:30AM  
Aug-26-20 09:00AM  
Aug-21-20 03:30PM  
Aug-12-20 08:30AM  
Aug-06-20 04:05PM  
Jul-30-20 08:30AM  
Jun-27-20 02:26PM  
Jun-03-20 11:34PM  
May-21-20 04:05PM  
May-18-20 04:05PM  
May-08-20 09:00AM  
Apr-30-20 08:30AM  
Apr-10-20 11:30AM  
Apr-08-20 10:17PM  
Mar-22-20 09:21AM  
Mar-13-20 09:18PM  
Mar-12-20 12:16PM  
Mar-11-20 04:05PM  
Mar-09-20 04:05PM  
Mar-04-20 08:30AM  
Feb-28-20 08:00AM  
Feb-25-20 08:30AM  
Jan-29-20 11:11AM  
Jan-28-20 11:14AM  
Jan-27-20 10:43AM  
Jan-23-20 09:34AM  
Jan-22-20 10:00AM  
Jan-09-20 04:09PM  
Dec-23-19 11:36AM  
Dec-19-19 08:30AM  
Dec-16-19 08:30AM  
Dec-13-19 08:30AM  
Dec-10-19 07:48PM  
Dec-09-19 08:00AM  
Dec-06-19 11:31AM  
Dec-03-19 09:00AM  
Nov-14-19 08:56AM  
Nov-07-19 11:26AM  
Nov-06-19 04:05PM  
Oct-31-19 02:13PM  
Oct-30-19 09:00AM  
Oct-25-19 07:12AM  
Oct-24-19 10:06PM  
Oct-23-19 07:00AM  
Sep-26-19 09:00AM  
Sep-24-19 10:20AM  
Sep-12-19 10:20PM  
Sep-11-19 10:44PM  
Sep-06-19 09:31AM  
Aug-28-19 07:27AM  
Aug-08-19 11:23AM  
Aug-07-19 04:18PM  
Aug-05-19 04:10PM  
Jul-31-19 09:00AM  
Jul-26-19 01:15PM  
Jun-26-19 07:19AM  
Jun-25-19 04:05PM  
Jun-24-19 09:00AM  
Jun-20-19 07:07PM  
Jun-10-19 04:01PM  
Jun-08-19 09:31AM  
May-30-19 11:02AM  
May-28-19 09:00AM  
May-23-19 01:04PM  
May-22-19 01:33AM  
May-15-19 09:00AM  
May-12-19 06:27PM  
May-10-19 10:51AM  
May-09-19 07:24PM  
May-08-19 10:38AM  
May-07-19 06:00AM  
May-06-19 02:53PM  
May-03-19 03:41PM  
May-02-19 11:44AM  
May-01-19 11:46AM  
Apr-26-19 02:04PM  
Apr-18-19 09:38AM  
Apr-17-19 11:01AM  
Apr-16-19 04:05PM  
Apr-15-19 10:50AM  
Apr-13-19 09:30AM  
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Medical Devices segment offers LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Strategic Positions segment develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PDL BIOPHARMA, INC.10% OwnerSep 29Buy11.168,70397,1258,667,397Oct 01 05:52 PM